title: A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
abstract: Trastuzumab (Herceptin; Genentech, Inc., CA, USA) is a humanized monoclonal antibody developed to target the HER-2/neu receptor, which is overexpressed in 20 - 25% of breast carcinomas. Clinical studies showed that trastuzumab is effective as single-agent therapy and that it has greater antitumour activity in combination with chemotherapy than chemotherapy alone in metastatic breast cancer. The indication for trastuzumab monotherapy and the combination with various chemotherapy agents is country-specific and is largely based on trials of efficacy and safety. Patients with a HER-2/neu overexpression level of 3+, determined by immunohistochemical assay or amplification using fluorescence in situ hybridisation, derive most clinical benefit from trastuzumab. Trastuzumab is generally well-tolerated. Cardiotoxicity is the main concern; thus, monitoring of cardiac function is recommended. Ongoing trials investigate the role of trastuzumab in the adjuvant and neoadjuvant settings.
authors.affiliation: Department of Gynecology and Obstetrics, Klinikum Grosshadern, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377 Munich, Germany. Sandra.Rueckert@med.uni-muenchen.de
authors.forename: S
authors.initials: S
authors.lastname: Rueckert
authors.forename: I
authors.initials: I
authors.lastname: Ruehl
authors.forename: S
authors.initials: S
authors.lastname: Kahlert
authors.forename: G
authors.initials: G
authors.lastname: Konecny
authors.forename: M
authors.initials: M
authors.lastname: Untch
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; D014747:Vinblastine; D000077235:Vinorelbine